<DOC>
	<DOCNO>NCT00685529</DOCNO>
	<brief_summary>The purpose study compare blood level arformoterol tartrate inhalation solution racemic formoterol male female subject mild moderate Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Study Arformoterol Tartrate Inhalation Solution Racemic Formoterol Subjects With Mild Moderate Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This open label , randomize , multiple dose , 3-way crossover , multicenter , inpatient outpatient study compare pharmacokinetic ( PK ) profile arformoterol tartrate inhalation solution Foradil® male female subject mild moderate COPD . Up 36 subject ( minimum 40 % gender ) randomize ensure minimum 24 subject complete study . The study include 3 dose period 3 washout period . Subjects receive 3 different treatment random order 13 consecutive day single dose morning 14th day . Subjects randomly assign 1 6 possible treatment sequence . During dose period , subject receive medication via nebulization DPI twice daily 13 consecutive day single dose morning 14th day . There 10 day washout period treatment . Subject participation approximately 13 week include screen visit 7 study visit . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female subject must least 35 year old time consent . Female subject less equal 65 year old must negative serum pregnancy test Visit 1 urine pregnancy test Visit 2 , confirm negative prior randomization . Subjects childbearing potential must use acceptable method birth control . Subjects must document primary clinical diagnosis nonasthmatic COPD Subjects must ≥ 15 packyear smoke history Subjects must general good health . Subjects must minimum blood pressure 105/60 mmHg minimum rest pulse 50 bpm Screening Visit 1 . Subjects must body mass index ( BMI ) least 16 kg/m2 30 kg/m2 . ( BMI define subject 's weight kilogram divide square subject 's height meter . ) Subjects must willing remain residential facility 3 separate 24 hour visit 3 separate 36hour visit . Subjects must agree refrain strenuous activity , define Principal Investigator , throughout study , screen visit end study/early termination visit . Subject febrile illness within 72 hour ( 3 day ) Screening . Subject clinically significant unstable medical abnormality , chronic disease , history clinically significant abnormality cardiovascular , respiratory , gastrointestinal , hepatic , renal system , , opinion investigator , may affect safety subject . Subject history malignancy currently malignancy non melanomatous skin cancer . Subjects cancerfree 5 year may enrol . Subjects chest xray suggest diagnosis COPD ( e.g. , diagnostic pneumonia , infection , atelectasis , pneumothorax active/ongoing pulmonary condition ) take within 6 month prior study start . If chest xray take within 6 month prior study start , recent result unavailable review , chest xray must perform . Subjects history asthma , exception asthma diagnose childhood . Subject test positive screen hepatitis B surface antigen hepatitis C antibody , subject history positive result . Subject know seropositive human immunodeficiency virus ( HIV ) . Female subject pregnant lactating . Female subject ( ) childbearing potential use contraception use hormonal contraception , ( b ) postmenopausal take form hormone replacement therapy . Subject disorder history condition may interfere drug absorption , distribution , metabolism , excretion ( e.g. , malabsorption , gastrointestinal surgery ) . Subject participate investigational study within 30 day prior screen currently participate another clinical trial . Subject staff member relative staff member . Subject positive urine alcohol test screening . Subjects know history alcohol use may enrol study subject 's alcohol use indicative abuse . Abuse define current consumption three alcoholic beverage per day . Subject history suspect history abuse barbiturate , amphetamine , narcotic and/or positive screening result substance study start . Subject history allergic reaction study medication component study medication . Subject receive oral anticoagulant therapy within 90 day Screening . Subject significant blood loss ( &gt; 500 cc ) donate blood within 60 day precede screen plan donate blood within 60 day complete study . Subject donate plasma within 72 hour prior first dose study drug . Subject acute illness within 10 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Arformoterol</keyword>
	<keyword>formoterol</keyword>
</DOC>